MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cancer & Oncology Companies _Pharmaceuticals & Biotechnology _ Leukemia, Hematologic, Blood
TScan Therapeutics, Inc. (NASDAQ: TCRX)
Organization & Developments: TScan Therapeutics
Parents
TScan Therapeutics, Inc. (NASDAQ: TCRX)
Children
*Clinical-stage biopharmaceutical company focused on the development of T cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of cancer.
2020: Novartis, TScan unite on TCR treatments for solid tumors
2020: Qiagen joins with T-cell biotech TScan to develop immune system test for COVID-19
2022: Tscan Therapeutics (TCRX) Investor Presentation - Slideshow_seekingalpha.com
2023: TScan Therapeutics Announces FDA Clearance of Three Investigational New Drug Applications for the Treatment of Solid Tumors
2023: TScan Therapeutics: That Recent Amgen Deal Is The Only Point Of Interest
2023: TScan: Two 2024 TCR-T Data Readouts Could Bring Significant Value_ seekingalpha
2024: TScan Therapeutics: Speculative Buy With Near-Term Catalysts In Oncology
2025: TScan: 2 Major Milestones Of TSC-101 To Carry Tide In 2025
Jumps
Finance & Acquisitions: TScan Therapeutics
Key People: TScan Therapeutics